Company profile

Apollo Therapeutics

A transformative idea for transformative medicines

Industry
Biotechnology Research
Employees
65

Apollo Therapeutics company summary

Apollo Therapeutics is a company in the Biotechnology Research industry. On LinkedIn the company has around 65 employees. Its listed specialties include Biotechnology, biopharmaceuticals, therapeutics, oncology, major inflammatory disorders.

What technology does Apollo Therapeutics use?

No technologies detected yet. Warmrank rechecks company websites on a rolling basis.

About Apollo Therapeutics

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners. Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. For more information, please visit our website at www.apollotherapeutics.com

Specialties

Biotechnologybiopharmaceuticalstherapeuticsoncologymajor inflammatory disordersrare disease

Compare companies similar to Apollo Therapeutics

More companies in Biotechnology Research.

CompanyIndustryEmployeesFoundedHeadquarters
Apollo Therapeutics
apollotherapeutics.com
Biotechnology Research65--
Thermo Fisher Scientific
thermofisher.com
Biotechnology Research100,779-Waltham, MA
Amgen
amgen.com
Biotechnology Research41,0281980Thousand Oaks, CA
Biogen
biogen.com
Biotechnology Research7,742-Cambridge, MA
Biocon
biocon.com
Biotechnology Research11,902-Bangalore, Karnataka
Biotechnology Research28,679-Bethesda, MD
Genentech
gene.com
Biotechnology Research18,2961976South San Francisco, California
Eurofins
eurofins.com
Biotechnology Research24,928-Luxembourg, Luxembourg
Gilead Sciences
gilead.com
Biotechnology Research14,743-Foster City, CA
Syneos Health
syneoshealth.com
Biotechnology Research23,772-Morrisville, NC
Moderna
modernatx.com
Biotechnology Research6,2382010Cambridge, Massachusetts

Frequently asked questions about Apollo Therapeutics

What does Apollo Therapeutics do?

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners. Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. For more information, please visit our website at www.apollotherapeutics.com

How many employees does Apollo Therapeutics have?

Apollo Therapeutics has around 65 employees on LinkedIn.

Build a lead list from companies like Apollo Therapeutics

Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.